Novo Nordisk A/S

NYSE:NVO

Drug Manufacturers - General

Healthcare
$39.43 -1.09%

-$0.48 today

Market cap
$173.82B
Beta
0.35
P/E (TTM)
10.2
EPS (TTM)
$27.45
Dividend yield
4.18%
52W Low $35.12High $74.38

Volume 16.12M

Average 16.05M

NVO Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Novo Nordisk A/SNYSE: NVO

Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026

Cash & equivalents rises 141.3% from a year ago

Cash & equivalents stood at DKK 44.48B at the end of Q2 FY2026, up 141.3% from a year earlier and up 110.5% from the prior quarter. Over 3 fiscal years it compounded at +27.9% a year.

Context

  • Cash & equivalents amounted to 7.5% of total assets at the end of Q2 FY2026, up 3.7 pp from a year earlier.
  • Cash & equivalents increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +141.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
DKK 44.48B+110.5% QoQ
Last fiscal yearDec 2025
DKK 26.46B+69.0% YoY
Year agoJun 2025
DKK 18.44B+141.3% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+141.3%——
1 year+69.0%——
3-year CAGR+27.9%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

DKK · from the balance sheet

Latest · FY2025
26.46B DKK
Year-over-year change
+69.0%
4-year CAGR
+25.3%

Cash & Equivalents vs competitors

How NVO compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +141.3% is the 2nd highest of 10, against a peer median of -7.2%.
  • Cash & equivalents amounts to 7.5% of total assets for NVO, versus a peer median of 5.3%.
NVO Competitors
Cash & Equivalents for NVO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NVONovo Nordisk A/SJun 2026DKK 44.48B DKK+141.3%+27.9%7.5%
JNJJohnson & JohnsonSep 2026$16.91B USD-7.2%+15.2%8.6%
AMGNAmgen Inc.Jun 2026$13.99B USD+74.3%+6.2%14.6%
LLYEli Lilly and CompanyJun 2026$8.89B USD+163.3%+51.3%6.2%
AZNAstraZeneca PLCSep 2026$7.92B USD-2.7%-2.5%6.6%
MRKMerck & Co., Inc.Jun 2026$6.85B USD-14.5%+4.7%5.3%
ABBVAbbVie Inc.Jun 2026$6.57B USD+1.6%-17.2%4.9%
SNYSanofiJun 2026€6.35B EUR-58.7%-15.6%4.9%
GSKGSK plcJun 2026£3.09B GBP-37.4%-3.1%5.0%
PFEPfizer Inc.Jun 2026$976M USD-40.4%+40.0%0.5%
Peer median (excluding NVO) —-7.2%+4.7%5.3%

Competitors are the stored peer set for NVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

DKK
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents10.72B12.65B14.39B15.66B26.46B
Short-term Investments6.77B10.92B15.84B10.65B498M
Net Receivables46.8B57.51B75.26B87.41B75.7B
Inventory19.62B24.39B31.81B40.85B49.62B
Other Current Assets1.69B9.67B2.34B6.33B20.17B
Total Current Assets85.6B108.19B139.65B160.9B172.45B
Property, Plant & Equipment (Net)55.36B66.67B90.96B162.49B208.38B
Goodwill4.35B5.09B4.46B20.06B19.85B
Intangible Assets38.83B46.32B55.94B91.03B110.21B
Long-term Investments1.44B1.34B1.66B2.68B2.51B
Tax Assets8.67B13.43B20.38B24.63B23.65B
Other Non-current Assets267M206M1.43B4.02B5.86B
Total Non-current Assets108.91B133.06B174.84B304.9B370.45B
Total Assets194.51B241.26B314.49B465.8B542.9B
Account Payables8.87B15.59B25.61B28.85B19.76B
Short-term Debt12.86B480M5.3B11.78B12.02B
Tax Payables3.66B7.09B7.12B9.72B0
Deferred Revenue00000
Other Current Liabilities73.3B96.8B38.14B165.85B175.47B
Total Current Liabilities99.52B120.94B169.66B217.53B215.66B
Long-term Debt9.65B20.78B15.98B84.25B110.37B
Deferred Tax Liabilities5.27B7.06B10.16B5.43B6.61B
Deferred Revenue (Non-current)00000
Other Non-current Liabilities6.01B5.45B7.58B9.68B7.64B
Total Non-current Liabilities24.25B36.83B38.27B104.78B133.19B
Total Liabilities123.76B157.77B207.93B322.31B348.86B
Common Stock462M456M451M446M446M
Retained Earnings72B80.59B104.84B144.45B195.3B
Accumulated OCI(1.71B)2.45B1.28B(1.41B)(1.7B)
Other Stockholders Equity00000
Minority Interest00000
Total Equity70.75B83.49B106.56B143.49B194.05B
Total Debt26.65B25.78B27.01B102.79B130.96B
Net Debt15.93B13.13B12.61B87.13B104.49B

Novo Nordisk A/S

NYSE:NVO

Intrinsic Alpha fair value

Locked

Current Price

$39.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.